Ventyx Biosciences
Fei Liu is a seasoned leader in the field of immunology with extensive experience in drug discovery and development. Currently serving as the Director of Immunology at Ventyx Biosciences since March 2018, Fei Liu is responsible for the scientific execution of multiple discovery programs, focusing on target identification, assay development, and preclinical proof-of-concept. Previous roles include Associate Director and Principal Scientist at Ventyx Biosciences, where Fei Liu developed pre-clinical in vitro/in vivo assays, and positions at Oppilan Pharma and Escalier Biosciences focused on similar areas. Fei Liu holds a Ph.D. in Immunology from Scripps Research and a Bachelor of Science in Chemistry from Lebanon Valley College.
This person is not in any teams
Ventyx Biosciences
1 followers
Ventyx Biosciences is a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high-value targets. Ventyx now includes combined assets from three separate companies: Oppilan Pharma, targeting S1P1R, Zomagen Biosciences, targeting NLRP3 and the inflammasome, and Ventyx Biosciences, targeting TYK2.